Clinical Trials Logo

Oral Submucous Fibrosis clinical trials

View clinical trials related to Oral Submucous Fibrosis.

Filter by:

NCT ID: NCT06332612 Not yet recruiting - Clinical trials for Oral Submucous Fibrosis

Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial

MROSF
Start date: March 2024
Phase: Phase 1/Phase 2
Study type: Interventional

OSF is a widespread health issue in Asian countries, notably Pakistan, linked to the consumption of pan, chalia, and gutka, affecting a rising number of young individuals as an epidemic. This condition significantly impairs oral function, resulting in ulcers and chronic lesions, often progressing to oral cancer. Current treatments focus on symptom relief and halting disease progression. This study explores the repurposing of metformin, an FDA-approved drug with antifibrotic properties, for OSF treatment. Our objective is to unveil its therapeutic potential and comprehend its impact on the dysregulated signaling pathways associated with OSF. This research offers promising insights for an enhanced management approach, providing hope for those grappling with this debilitating condition

NCT ID: NCT05660694 Completed - Tumor Clinical Trials

Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis

Start date: January 1, 2020
Phase: Phase 4
Study type: Interventional

To compare the efficacy of Triamcinolone with Pentoxifylline and Vitamin E in patients with stage two and three oral submucous fibrosis.

NCT ID: NCT04487938 Not yet recruiting - Oral Cancer Clinical Trials

Oral Cancer Screening and Education in Hong Kong

Start date: August 1, 2021
Phase:
Study type: Observational

This study will be conducted to obtain data on oral cancer risk factors to generate machine learning models with good predictive accuracy for stratifying individuals with high-oral cancer risk and delineating high-risk and low-risk oral lesions. Likewise, this study will seek to provide oral cancer-related health education and training on oral-self-examination for beneficiaries

NCT ID: NCT04476420 Completed - Clinical trials for Oral Submucous Fibrosis

Comparative Effect of Nigella Sativa and Conventional Management for OSMF

Start date: February 11, 2021
Phase: Phase 3
Study type: Interventional

Oral submucous fibrosis (OSMF) is a potentially malignant condition mainly characterized by inflammation and fibrosis of the submucosal tissues leading to marked rigidity and reduced opening of the jaws. OSMF has a multifactorial etiology but areca nut consumption is considered to be the most consistent factor in its pathogenesis. There is no definitive treatment available for treating OSMF. Conventional management involves physiotherapy exercises and treating the disease with certain medications such as steroids and homeopathic medications.

NCT ID: NCT04153266 Completed - Quality of Life Clinical Trials

Oral Epithelial Dysplasia Informational Needs Questionnaire

ODIN-Q
Start date: October 31, 2018
Phase:
Study type: Observational

Background: Oral epithelial dysplasia (OED) is a condition with an increased risk of oral cancer. Due to the current changes in the factors associated with these diseases (because of human papillomavirus), it is expected that those who have no history of smoking or alcohol, young (<50 years old), and white male would be commonly affected. Those individuals require a higher need for information, preferred a more active role in decision-making, and have a longer lifespan than older individuals. There remain no detailed studies of whether the informational needs delivered to patients with OED met their needs or indeed what information such patient may wish. A few tools are available to evaluate the IN of patients with head and neck disorders. However, the items of these instruments were dedicated to a particular disease (e.g. cancer) and hence are not applicable to be used for OED. Project aims: To evaluate the psychometric properties of the Oral Epithelial Dysplasia Informational Needs Questionnaire (ODIN-Q), developed and revised in the preliminary work for the proposed study, in a cohort of patients with OED. Timescale: 19 months. Clinical significance: This questionnaire can be useful in clinical practice. It could help to meet the patient's information needs and plan educational interventions for those showing unmet needs.

NCT ID: NCT03732872 Completed - Clinical trials for Oral Submucous Fibrosis

Epithelial Mesenchymal Transition Markers in OSMF

Start date: January 15, 2015
Phase:
Study type: Observational

Oral Sub mucous Fibrosis (OSMF) is essentially an imbalance between collagen metabolism and wound healing mechanism induced by arecanut chewing habit. Clinically the disease progresses in stages with patients presenting with burning sensation, intolerance to spicy food, vesicles particularly on the palate, ulceration and dryness of the mouth , fibrosis of the oral mucosa, leading to lips, tongue, and palate rigidity and finally trismus. As the disease is progressively debilitating and has potential to turn in to malignant cancer a study was designed to assess if there any tissue or saliva markers that can be assessed for early diagnosis and indicate malignant transformation if any. Participants who had OSMF and habit history, patients without OSMF but habit history formed the case group where as normal patients without OSMF and no habit history were in control group. Eligible candidates who consented to participate in study were subjected to biopsy procedure and also their saliva samples were collected. Biopsy samples were subjected to immunohistochemistry (IHC) and polymerase chain reaction (PCR) to assess the EMT markers like vimentin, e-cadherin and collagen IV. miRNA copies were extracted from saliva and were subjected RT-PCR. Research question was: 1. Is EMT a positive signature in OSMF. 2. Does histopathological grading and dysplasia in OSMF have any correlation with EMT. 3. Can aberrant EMT markers be a reliable indicator for risk assessment of early malignant transformation. 4. Can expression of mi RNA 21 in saliva predict the disease severity and more importantly assess risk of early malignant transformation in OSMF.

NCT ID: NCT03511261 Recruiting - Clinical trials for Oral Submucous Fibrosis

Efficacy of Curcumin in Oral Submucous Fibrosis

ECOSMF
Start date: January 2014
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether the formulations of curcumin will effect the clinical signs and symptoms and histopathological features in patients with clinical stage 2 oral submucous fibrosis (OSMF).

NCT ID: NCT03011086 Completed - Clinical trials for Oral Submucous Fibrosis

Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis

Start date: January 2015
Phase: N/A
Study type: Observational

The etiology of OSMF is considered to be multifactorial. However, Role of autoimmunity had been suggested as one of the factors but remains unproven. The present study is undertaken to evaluate the presence of auto antibodies in OSMF patients to pave a way for new arena of treatment with the etiology of this persistent condition

NCT ID: NCT02711046 Completed - Clinical trials for Oral Submucous Fibrosis

Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis

Start date: March 2011
Phase: N/A
Study type: Interventional

Long standing oral submucous fibrosis(OSMF) is associated with involvement of the oral submucosa and the muscles of mastication leading to difficulty in mouth opening. Various surgical modalities are mentioned for release but each has its own limitations.The aim of the study was to evaluate the change in mouth opening in patients of OSMF after excision of fibrous bands followed by coronoidotomy and surgical defect coverage by single stage nasolabial flap.

NCT ID: NCT02645656 Active, not recruiting - Clinical trials for Oral Submucous Fibrosis

Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF)

Start date: December 2013
Phase: Phase 2
Study type: Interventional

Curcumin (diferuloylmethane) is the chief component of the spice turmeric and is derived from the rhizome of the East Indian plant Curcuma longa. Curcuma longais a member of the Zingiberacae (ginger) family of botanicals and is a perennial plant that is native to Southeast Asia. Turmeric contains a class of compounds known as the curcuminoids, comprised of curcumin, demethoxy curcumin and bisdemethoxycurcumin.